Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+17.95%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$10.2B
AUM Growth
+$1.96B
(+24%)
Cap. Flow
+$684M
Cap. Flow
% of AUM
6.68%
Top 10 Holdings %
Top 10 Hldgs %
43.19%
Holding
1,081
New
132
Increased
418
Reduced
456
Closed
74
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
$295M |
| 2 |
VanEck Gold Miners ETF
GDX
|
$118M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
$97.9M |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
$55.8M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
$27.6M |
Top Sells
| 1 |
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
$107M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
$32.9M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
$17.7M |
| 4 |
Lockheed Martin
LMT
|
$13.5M |
| 5 |
Apple
AAPL
|
$10.9M |
Sector Composition
| 1 | Technology | 26.66% |
| 2 | Financials | 16.65% |
| 3 | Industrials | 3.24% |
| 4 | Energy | 3.1% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Denali Therapeutics
DNLI
$2.26B
| $976K | 0.01% |
11,650
-27,468
| -70% | -$2.3M |
|
502
Amicus Therapeutics
FOLD
$2.46B
| $974K | 0.01% |
42,180
-111,751
| -73% | -$2.58M |
|
503
Acadia Pharmaceuticals
ACAD
$4.26B
| $972K | 0.01% |
18,186
-35,995
| -66% | -$1.92M |
|
504
Halozyme
HALO
$8.76B
| $970K | 0.01% |
22,710
-50,641
| -69% | -$2.16M |
|
505
Alaska Air
ALK
$7.28B
| $969K | 0.01% |
18,633
+5,008
| +37% | +$260K |
|
506
Southwest Airlines
LUV
$16.5B
| $968K | 0.01% |
20,774
+6,282
| +43% | +$293K |
|
507
Arrowhead Research
ARWR
$4.02B
| $966K | 0.01% |
12,587
-47,158
| -79% | -$3.62M |
|
508
Natera
NTRA
$23.1B
| $961K | 0.01% |
9,655
-23,632
| -71% | -$2.35M |
|
|
XLRN
509
DELISTED
Acceleron Pharma Inc.
XLRN
| $960K | 0.01% |
7,501
-14,448
| -66% | -$1.85M |
|
|
TPTX
510
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $958K | 0.01% |
7,859
-17,350
| -69% | -$2.11M |
|
511
Bankunited
BKU
$2.93B
| $955K | 0.01% |
27,455
-13,351
| -33% | -$464K |
|
512
GE Aerospace
GE
$296B
| $954K | 0.01% |
17,718
+6,719
| +61% | +$362K |
|
513
Intellia Therapeutics
NTLA
$1.29B
| $952K | 0.01% |
17,504
-64,161
| -79% | -$3.49M |
|
|
CCXI
514
DELISTED
ChemoCentryx, Inc.
CCXI
| $951K | 0.01% |
15,355
-25,920
| -63% | -$1.61M |
|
515
Jazz Pharmaceuticals
JAZZ
$7.86B
| $950K | 0.01% |
5,758
+410
| +8% | +$67.6K |
|
516
Sarepta Therapeutics
SRPT
$1.96B
| $950K | 0.01% |
5,574
-9,607
| -63% | -$1.64M |
|
517
Exelixis
EXEL
$10.2B
| $942K | 0.01% |
46,916
-44,393
| -49% | -$891K |
|
518
Delta Air Lines
DAL
$39.9B
| $940K | 0.01% |
23,369
+9,285
| +66% | +$373K |
|
519
Seres Therapeutics
MCRB
$169M
| $938K | 0.01% |
+1,915
| New | +$938K |
|
520
Alnylam Pharmaceuticals
ALNY
$59.2B
| $934K | 0.01% |
7,189
-9,017
| -56% | -$1.17M |
|
521
Sangamo Therapeutics
SGMO
$165M
| $934K | 0.01% |
59,861
-128,740
| -68% | -$2.01M |
|
|
DCPH
522
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $934K | 0.01% |
16,361
-26,269
| -62% | -$1.5M |
|
523
Procter & Gamble
PG
$375B
| $933K | 0.01% |
6,702
-2,205
| -25% | -$307K |
|
524
Adverum Biotechnologies
ADVM
$73.9M
| $930K | 0.01% |
8,583
-7,452
| -46% | -$807K |
|
525
Twist Bioscience
TWST
$1.55B
| $930K | 0.01% |
6,581
-25,161
| -79% | -$3.56M |
|